McNeil CJ, Williamson JC, and Muzny CA. Successful treatment of persistent 5-nitroimidizole-resistant trichomoniasis with an extended course of oral secnidazole plus intravaginal boric acid. Sex Transm Dis 2023;50:243-6. PMID: 36730040

 

Yoshizawa K, et al. Poly(2-methoxyethyl acrylate) (PMEA) improves the thromboresistance of FRED flow diverters: a thrombogenic evaluation of flow diverters with human blood under flow conditions. J Neurointervent Surg Epub ahead of print. PMID: 36180206

 

Muzny CA, Van Gerwen OT, and Legendre D. Secnidazole: a treatment for trichomoniasis in adolescents and adults. Expert Rev Anti-infect Ther 2022;20:1067-76. PMID: 35642509

 

Muzny, CA and Van Gerwen OT. Secnidazole for trichomoniasis in women and men. Sex Med Rev 2022;10:255-62. PMID: 35153156

 

Muzny CA, Nyirjesy P, and Chavoustie SE. A new treatment for trichomoniasis: single-dose secnidazole. Educational Supplement to Contemporary OB/GYN. September, 2021 [pdf].

 

Seña AC, et al.[1] Bacterial vaginosis and its association with incident Trichomonas vaginalis infections: a systematic review and meta-analysis. Sex Transm Dis 2021;48:e192-201. PMID: 34433796

 

Muzny CA, et al. Efficacy and safety of single oral dosing of secnidazole for trichomoniasis in women: results of a phase 3, randomized, double-blind, placebo-controlled, delayed-treatment study. Clin Infect Dis 2021. PMID: 33768237

 

Barratt J, et al. Efficacy and cardiovascular safety of roxadustat in dialysis-dependent chronic kidney disease: pooled analysis of four phase 3 studies. Adv Ther 2021;38:5345-60. PMID: 34523074

 

Charytan C, et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney Int Rep 2021;6:1829-39. PMID: 34307977

 

Coyne DW, et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney Int Rep 2021;6:624-35. PMID: 33732977

 

Fishbane S, et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study. J Am Soc Nephrol 2021;32:737-55. PMID: 33568383

 

Provenzano R, et al. Efficacy and cardiovascular safety of roxadustat for treatment of anemia in patients with non-dialysis-dependent CKD: pooled results from three randomized clinical trials. Clin J Am Soc Nephrol 2021;16:1190-1200. PMID: 34362786

 

Provenzano R, et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrol Dial Transplant 2021;25:gfab051. PMID: 33629100

 

Provenzano R, et al. Pooled analysis of roxadustat for anemia in patients with kidney failure incident to dialysis. Kidney Int Rep 2021;6:613-23. PMID: 33732976

 

Park YD, et al. Long-term efficacy and safety of cannabidiol (CBD) in children with treatment-resistant epilepsy: results from a state-based expanded access program. Epilepsy Behav 2020;112:107474. PMID: 33181893

 

VanLandingham K, et al. A phase 2, double-blind, placebo-controlled trial to investigate potential drug-drug interactions between cannabidiol and clobazam. J Clin Pharmacol 2020;doi10.1002/jcph.1634. PMID: 32652616

 

Taylor L, Crockett J, Tayo B, et al. Abrupt withdrawal of cannabidiol (CBD): A randomized trial. Epilepsy Behav 2020;104:106938. PMID: 32036242

 

Wroblewski J, McChancy C, Pickel K, et al. Reproducibility of fixed-luminance and multi-luminance flicker electroretinography in patients with diabetic retinopathy using an office-based testing paradigm. J Diabetes Sci Technol 2019. doi: 10.1177/1932296819882719. PMID: 31640411

 

Laux LC, Bebin EM, Checketts D, et al. Long-term safety and efficacy of cannabidiol in children and adults with treatment-resistant Lennox-Gastaut syndrome or Dravet syndrome: expanded access program results. Epilepsy Res 2019;154:13-20. PMID: 31022635

 

Guzzi LM, Bergler T, Binnall B, et al. Clinical use of [TIMP-2]•[IGFBP7] biomarker testing to assess risk of acute kidney injury in critical care: guidance from an expert panel. Critical Care 2019;23:225. PMID: 31221200

 

Szaflarski JP, Bebin EM, Comi AM, et al. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results. Epilepsia 2018;59:1540-8. PMID: 29998598

 

Sanborn GE, Wroblewski JJ. Evaluation of a combination digital retinal camera with spectral-domain optical coherence tomography (SD-OCT) that might be used for the screening of diabetic retinopathy with telemedicine: a pilot study. J Diabetes Complications 2018;32:1046-50. PMID: 30121204

 

Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018;391:1085-96. PMID: 29395273

 

DuPont HL, Wolf RA, Olin JT, Pimentel M. Antimicrobial susceptibility of Staphylococcus isolates from the skin of patients with diarrhea-predominant irritable bowel syndrome treated with repeat courses of rifaximin. Antimicrob Agents Chemother 2017;61:e02165-16. PMID: 27795384

 

Mead, A. The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law. Epilepsy Behav 2017;70:288-91. PMID: 28169144

 

Saida T, Yamamura T, Kira J, et al. Long-term safety and efficacy of natalizumab in Japanese patients with relapsing-remitting multiple sclerosis: 1-year interim results from a phase 2, open-label extension study. Mult Scler Relat Disord 2017;11:25-31. PMID: 28104251

 

Watson C, Prosser C, Braun S, et al. Healthcare resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany. Clinicoecon Outcomes Res 2017;9:85-97. PMID: 28203098

 

Burke CA, Dekker E, Samadder NJ, et al. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial. BMC Gastroenterol 2016;16:87. doi: 10.1186/s12876-016-0494-4. PMID: 27480131

 

Iribarren C, Rothman KJ, Bradley MS, et al. Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials. J Allergy Clin Immunol 2017;139:1489-95. PMID: 27639934

 

Wroblewski JJ and Hu AY. Topical squalamine 0.2% and intravitreal ranibizumab 0.5mg as combination therapy for macular edema due to branch and central retinal vein occlusion: an open-label, randomized study. OSLI Retina 2016;47:914-23. PMID: 27759857

 

Radue EW, Sprenger T, Vollmer T, et al. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2016;23:412-5. PMID: 26806217

 

Warwick D, Arner M, Pajardi G, et al. Collagenase Clostridium histolyticum in patients with Dupuytren’s contracture: results from POINT X, an open-label study of clinical and patient-reported outcomes. J Hand Surg Eur 2015;40:124-32. PMID: 24470559

 

Cudkowicz ME, Titus S, Kearney M, et al, on behalf of the Ceftriaxone Study Investigators. Efficacy and safety of ceftriaxone for amyotrophic lateral sclerosis: results of a multi-stage, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol 2014;13:1083-91. PMID: 25297012

 

Chio A, Logroscino G, Traynor BJ, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 2013;41:118-30. PMID: 23860588

 

Rudnicki SA, Berry JD, Ingersoll E, et al. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: Subgroup analysis of demographic and clinical characteristics. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:44-51. PMID: 22985432

 

Hayton MJ, Bayat A, Chapman DS, et al. Isolated and spontaneous correction of proximal interphalangeal joint contractures in Dupuytren’s disease: an exploratory analysis of the efficacy and safety of collagenase Clostridium histolyticum. Clin Drug Investig 2013;33:905-12. PMID: 24092562

 

Dias J, Bainbridge C, Leclercq C, et al. Surgical management of Dupuytren’s contracture in Europe: regional analysis of a surgeon survey and patient chart review. Int J Clin Pract 2013;67:271-81. PMID: 23409695

 

Dahlin LB, Bainbridge C, Leclercq C, et al. Dupuytren’s disease presentation, referral patterns, and resource utilization in Europe: regional analysis of a surgeon survey and patient chart review. Int J Clin Pract 2013;67:261-70. PMID: 23409694

 

van Dijk D, P Finigan, RA Gerber, et al. Recognition, diagnosis and referral of patients with Dupuytren’s disease: a review of current concepts for general practitioners in Europe. Curr Med Res Opin 2013;29:269-77. PMID: 23320611

 

Bainbridge C, RA Gerber, PP Szczypa, et al. Efficacy of collagenase in patients who did and did not have previous hand surgery for Dupuytren’s contracture. J Plast Surg Hand Surg 2012;46:177-83. PMID: 22670890

 

Gollar KM, Young DG, Bailen J, et al. Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study. Urol Nurs 2012;32:38-46. PMID: 22474864

 

Gerber RA, R Perry, R Thompson, C Bainbridge. Dupuytren’s contracture: a retrospective database analysis to assess clinical management and costs in England. BMC Musculoskelet Disord 2011;12:73-83. PMID: 21486483

 

Witthaut J, AG Bushmakin, RA Gerber, et al. Determining clinically important changes in range of motion in patients with Dupuytren’s contracture: secondary analysis of the randomized, double-blind, placebo-controlled CORD I study. Clin Drug Invest 2011;31:791-8. PMID: 21967070

 

Crosby RD, Mathias SD, Marshall T. Relationships between changes in overactive bladder symptoms and in subjective assessments of symptom bother and health-related quality of life in patients taking solifenacin or placebo in the VIBRANT study. Int J Clin Pract 2011;65:211-8. PMID: 21235700

 

Vardy M, Mitcheson HD, Samuels T-A, et al. Efficacy of solifenacin on overactive bladder symptoms, symptom bother, and other patient-reported outcomes in subjects with or without incontinence: a post hoc analysis of data from VIBRANT. Female Pelvic Med Reconstr Surg 2011;17:24-9. PMID: 22453669

 

Lucente V, Ostergard D, Davila W, et al. Efficacy of solifenacin on symptom bother and health-related quality of life in patients with acute, early chronic, and late chronic overactive bladder: secondary analysis of data from the VOLT study. Female Pelvic Med Reconstruct Surg 2010;16:320-6. PMID: 22453614

 

Toglia MR, Ostergard DR, Appell RA, et al. Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. Int Urogynecol J 2010;21:847-54. PMID: 20339833

 

Kaplan S, Goldfischer E, Steers W, et al. Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes. Aging Male 2010;13:100-7. PMID: 20001469

 

Toglia M, Serels SR, Laramée C, et al. Solifenacin for overactive bladder: patient-reported outcomes from a large, placebo-controlled trial. Postgrad Med 2009;121:151-8. PMID: 19820284

 

Vardy MD, Mitcheson HD, Samuels T-A, et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT – a double-blind, placebo-controlled trial. Int J Clin Pract 2009;63:1702-14. PMID: 19930331

 

Griebling TL, Kraus SR, Richter HE, et al. Tolterodine extended release is well tolerated in older subjects. Int J Clin Pract 2009;63:1198-1204. PMID: 19624787

 

Coyne KS, Elinoff V, Gordon DA, et al. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine. Int J Clin Pract 2008;62:925-31. PMID: 18479285

 

Irwin DE, Abrams P, Milsom I, et al. Understanding the elements of overactive bladder: questions raised by the EPIC study. BJU Int 2008;101:1381-7. PMID: 18336602

 

Kaplan SA, Roehrborn CG, Chancellor M, et al. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU Int 2008;102:1133-9. PMID: 18510659

 

Kaplan SA, Wein AJ, Staskin DR, et al. Urinary retention and post-void residual urine in men: separating truth from tradition. J Urol 2008;180:47-54. PMID: 18485378

 

Roehrborn CG, Kaplan SA, Kraus SR, et al. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology 2008;72:1061-7. PMID: 18817961

 

Rovner ES, Kreder K, Sussman DO, et al. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol 2008;180:1034-41. PMID: 18639297

 

Rovner ES, Rackley R, Nitti VW, et al. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder. Urology 2008;72:488-93. PMID: 18639327

 

Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007;100:987-1006. PMID: 17922784

 

Dmochowski R, Abrams P, Marschall-Kehrel D, et al. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol 2007;51:1054-64. PMID: 17097217

 

Dmochowski R, Kreder K, MacDiarmid S, et al. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder. BJU Int 2007;100:107-10. PMID: 17552957

 

Kaplan S. New data on tolterodine: do recent findings dispel questions about treating overactive bladder in men? Eur Urol Suppl 2007;6:10-16.

 

Sussman DO, Kraus SR, Carlsson M, Guan Z. Onset of efficacy of tolterodine extended release in patients with overactive bladder. Curr Med Res Opin 2007;23:777-81. PMID: 17407634

 

Wein AJ, Khullar V, Wang JT, Guan Z. Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU Int 2007;99:360-3. PMID: 17155987

 

Weiss JP, Blaivas JG, Jones M, et al. Age related pathogenesis of nocturia in patients with overactive bladder. J Urol 2007;178:548-51. PMID: 17570424

 

Abrams P, Artibani W, Gajewski JB, Hussain I. Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology 2006;68:17-28. PMID: 16908337

 

Abrams P, Kaplan S, De Koning Gans HJ, R Millard. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006;175:999-1004. PMID: 16469601

 

Brubaker L, Chapple C, Coyne KS, Kopp Z. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology 2006;68:3-8. PMID: 16908335

 

Coyne KS, Tubaro A, Brubaker L, Bavendam T. Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. Urology 2006;68:9-16. PMID: 16908336

 

Elinoff V, Bavendam T, Glasser DB, et al. Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. Int J Clin Pract 2006;60:745-51. PMID: 16805763

 

Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-15. PMID: 17049716

 

Jonas U, Rackley RR. Re: Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2006;49:187-8. PMID: 16310930

 

Kaplan SA, Roehrborn CG, Dmochowski R, et al. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 2006;68:328-32. PMID: 16904446

 

Khullar V, Chapple C, Gabriel Z, Dooley JA. The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis. Urology 2006;68:38-48. PMID: 16908339

 

Marschall-Kehrel D, Roberts RG, Brubaker L. Patient-reported outcomes in overactive bladder: the influence of perception of condition and expectation for treatment benefit. Urology 2006;68:29-37. PMID: 16908338

 

Nitti VW, Dmochowski R, Appell RA, et al. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. BJU Int 2006;97:1262-6. PMID: 16686723

 

Rackley R, Weiss JP, Rovner ES, et al. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 2006;67:731-6. PMID: 16618562

 

Roberts R, Bavendam T, Glasser DB, et al. Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial. Int J Clin Pract 2006;60:752-8. PMID: 16805764

 

Roehrborn CG, Abrams P, Rovner ES, et al. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int 2006;97:1003-6. PMID: 16643482

 

Ellsworth PI, NG Borgstein, RJM Nijman, PP Reddy. Use of tolterodine in children with neurogenic detrusor overactivity: Relationship between dose and urodynamic response. J Urol 2005;174:1647-51. PMID: 16148673

 

Katz SD, Parker JD, Glasser DB, et al. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. Am J Cardiol 2005;95:36-42. PMID: 15619391

 

Montorsi F, McCullough AR. Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: A systematic review. J Sex Med 2005;2:658–67. PMID: 16422824

 

Nijman RJM, Borgstein NG, Ellsworth P, Djurhuus JC. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: Results from 2 randomized placebo-controlled trials. J Urol 2005;173:1334-9. PMID: 15758796

 

DeBusk RF, Pepine CJ, Glasser DB, et al. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am J Cardiol 2004;93:147-53. PMID: 14715338

 

Pickering TG, Shepherd AMM, Puddey I, et al. Sildenafil citrate in men with erectile dysfunction taking multiple antihypertensives: A randomized controlled trial. Am J Hypertens 2004;17:1135-42. PMID: 15607620

 

Tignol J, Furlan PM, Gomez-Beneyto M, et al. Efficacy of sildenafil citrate (Viagra®) for the treatment of erectile dysfunction in men in remission from depression. Int Clin Psychopharmacol 2004;19:191-9. PMID: 15201565

 

Mittleman MA, Glasser DB, Orazem J. Clinical trials of sildenafil citrate (Viagra®) demonstrate no increase in risk of myocardial infarction and cardiovascular death compared with placebo. Int J Clin Pract 2003;57:597-600. PMID: 14529061

 

Nurnberg, HG, Hensley PL, Gelenberg AJ, et al. Treatment of antidepressant-associated sexual dysfunction with sildenafil: A randomized controlled trial. JAMA 2003;289:56-64. PMID: 12503977

 

Derry F, Hultling C, Seftel AD, Sipski ML. Efficacy and safety of sildenafil citrate (Viagra®) in men with erectile dysfunction and spinal cord injury: A review. Urology 2002;60:49-57. PMID: 12414333

 

Nurnberg HG, Seidman SN, Gelenberg AJ, et al. Depression, antidepressant therapies, and erectile dysfunction: Clinical trials of sildenafil citrate (Viagra®) in treated and untreated patients with depression. Urology 2002;60:58-66. PMID: 12414334

 

Padma-Nathan H, Eardley I, Kloner RA, et al. A 4-year update on the safety of sildenafil citrate (Viagra®). Urology 2002;60:67-90. PMID: 12414335

 

 

Assisted with literature review and/or data analysis

Baker JW, Reshef A, Moldovan D, et al. Recombinant human C1-esterase inhibitor to treat acute hereditary angioedema attacks in adolescents. J Allergy Clin Immunol Pract 2017;5:1091-7. PMID: 28202404

 

Dimopoulos MA, Stewart AK, Masszi T, et al. Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer J 2017;7:e554. PMID: 28430175

 

Kane CJ, Eggener SE, Shindel AW, Andriole GL. Variability in outcomes for patients with intermediate-risk prostate cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2-3) and implications for risk stratification. Eur Urol Focus 2017;3:487-97. PMID: 28753804

 

Rosen VM, Guerra I, McCormack M, et al. Systematic review and network meta-analysis of bevacizumab plus first-line topotecan-paclitaxel or cisplatin-paclitaxel versus non–bevacizumab-containing therapies in persistent, recurrent, or metastatic cervical cancer. Int J Gynecol Cancer 2017;27:1237-46. PMID: 28448304

 

 

Academic publications

Goldstein LA, Spurlock CW. Kentucky’s child restraint law has saved lives: A 20-year review of fatalities among children (aged 0–4) as motor vehicle occupants. KY Med Assoc J 1998;96:97-100. (cover story) PMID: 9529830

 

Struttmann, T, Scheerer A, Prince T, Goldstein LA. Unintentional carbon monoxide poisoning from an unlikely source. J Amer Board Fam Prac 1998:11;481-4. PMID: 9876005

 

Goldstein, LA, Spurlock CW, Kidd PA. Economic costs of motor vehicle crashes (MVCs) involving teenaged drivers. Inj Prev 1997;3:200-6. PMID: 9338832

 

Porter JD, Goldstein LA, Kasarskis EJ, Brueckner JK, Spear BT. The neuronal voltage-gated sodium channel, Scn8a, is essential for postnatal maturation of spinal, but not oculomotor, motor units.  Exp Neurol 1996;139:328-34. PMID: 8654536

 

Goldstein LA, Mills AC, Sengelaub DR. Motoneuron development after deafferentation: I. Dorsal rhizotomy does not alter the growth the spinal nucleus of the bulbocavernosus (SNB). Dev Brain Res 1996;91:11-9. PMID: 8821475

 

Hays TC, Goldstein LA, Mills AC, Sengelaub DR. Motoneuron development after deafferentation: II. Dorsal rhizotomy does not block estrogen-supported growth of the dorsolateral nucleus (DLN). Dev Brain Res 1996;91:20-8. PMID: 8821476

 

Goldstein LA, Sengelaub DR. Differential effects of dihydrotestosterone and estrogen on motoneuron dendritic growth and morphology in the spinal nucleus of the bulbocavernosus. J Neurobiol 1994;25:878-92. PMID: 8089663

 

Goldstein LA, Sengelaub DR. Dendritic growth and morphology of motoneurons in the dorsolateral nucleus (DLN) of the rat spinal cord: Normal development and androgen regulation. J Comp Neurol 1993;338:588-600. PMID: 7510730

 

Goldstein LA, Kurz EM, Kalkbrenner AE, Sengelaub DR. Changes in dendritic morphology of rat spinal motoneurons during development and after unilateral target deletion. Dev Brain Res 1993;73:151-63. PMID: 8353928

 

Goldstein LA, Sengelaub DR. Timing and duration of dihydrotestosterone treatment affect the development of motoneuron number and morphology in a sexually dimorphic rat spinal nucleus. J Comp Neurol 1992;326:147-57. PMID: 1479067

 

Goldstein LA, Sengelaub DR. Hormonal control of neuron number in sexually dimorphic nuclei in the rat spinal cord. IV. Masculinization of the Spinal Nucleus of the Bulbocavernosus with testosterone metabolites. J Neurobiol 1990;21:719-30. PMID: 2394988

 

Goldstein LA, Kurz EM Sengelaub DR. Androgen regulation of dendritic growth and retraction in the development of a sexually dimorphic spinal nucleus. J Neurosci 1990;10:935-46. PMID: 2319307

 

 

Non-refereed articles

Goldstein LA, Spurlock CW, Kidd PA, McCool RH. Economic impact of motor-vehicle crashes involving teenaged drivers—Kentucky, 1994. MMWR 1996;45:715-9. PMID: 8769653

 

Goldstein LA, Spurlock CW. Kentucky’s child restraint law has saved lives: A review of the past 20 years. KY Epidemiol Notes Rep 1996;31:2-4.

 

Goldstein LA. Teenage motor vehicle crashes in Kentucky: Morbidity and mortality rates and economic costs. KY Epidemiol Notes Rep 1996;31:2-4.

 

 

Abstracts/Conference Presentations

Kovanic-Spiro P and Goldstein LA. “Think First For Kids” in Pittsburgh’s Elementary Schools: Implementation and Evaluation. APHA Abstr 2000.

 

Goldstein LA. Youth Violence Prevention and Injury Reduction Initiative: One-Year Review. APHA Abstr 2000.

 

Clontz A, Byrdsong TR, Goldstein LA, Marin RS, Schuh R. A community-university collaboration to prevent youth violence. Am Trauma Soc Abstr 2000.

 

Svenson JE, Spurlock CW, Goldstein LA. Population-based incidence of brain injuries: Surveillance utilizing an emergency department database. 4th International Injury Conference, 1997.

 

Goldstein LA, RH McCool, PA Kidd and CW Spurlock. Reassessing the costs of teenage motor vehicle crashes. APHA Abstr 1996;124:214.

 

Kasarskis EJ, Goldstein LA, Porter JD, Spear BT. The mndlex mouse, a new murine model of motor neuron disease. Ann Neurol 1994;36:285.

 

Goldstein LA, Kasarskis EJ, Spear BT, Porter JD. Postnatal neuromuscular degeneration in a new transgenic mouse model of motor neuron disease. Soc Neurosci Abstr 1994;20:199.

 

Goldstein LA, Mills AC, Sengelaub DR. Dorsal rhizotomy does not alter development of motoneuron morphology in the spinal nucleus of the bulbocavernosus. Soc Neurosci Abstr 1993;19:1311.

 

Goldstein LA, Sengelaub DR. Hormonal control of dendritic development in sexually dimorphic rat spinal nuclei. Soc Neurosci Abstr 1991;17:1318.

 

Goldstein LA, Sengelaub DR. Timing and duration of DHT treatment alter motoneuron number, morphology and specificity in a sexually dimorphic rat spinal nucleus. Soc Neurosci Abstr 1990;16:328.

 

Goldstein LA, Sengelaub DR. Androgen metabolites masculinize motoneuron number in a sexually dimorphic rat spinal nucleus. Soc Neurosci Abstr 1989;15:87.

 

Kurz EM, Goldstein LA, Sengelaub DR. Evidence for dendritic competition in the development of motoneuron morphology in the rat spinal cord. Soc Neurosci Abstr 1989;15:67.

 

Goldstein LA, Kurz, EM, Sengelaub DR. Androgens regulate dendritic growth during postnatal development of sexually dimorphic motoneurons. Soc Neurosci Abstr 1988;14:706.